Form 8-K - Current report:
SEC Accession No. 0001193125-26-059490
Filing Date
2026-02-19
Accepted
2026-02-19 16:27:56
Documents
18
Period of Report
2026-02-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d106293d8k.htm   iXBRL 8-K 33824
2 EX-1.1 d106293dex11.htm EX-1.1 141857
3 EX-4.2 d106293dex42.htm EX-4.2 214634
4 EX-5.1 d106293dex51.htm EX-5.1 17356
9 GRAPHIC g106293g09p68.jpg GRAPHIC 6066
10 GRAPHIC g106293g94u94.jpg GRAPHIC 3618
  Complete submission text file 0001193125-26-059490.txt   657778

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA amgn-20260217.xsd EX-101.SCH 3870
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE amgn-20260217_def.xml EX-101.DEF 13250
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE amgn-20260217_lab.xml EX-101.LAB 21838
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amgn-20260217_pre.xml EX-101.PRE 14153
21 EXTRACTED XBRL INSTANCE DOCUMENT d106293d8k_htm.xml XML 5515
Mailing Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Business Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 (805)447-1000
AMGEN INC (Filer) CIK: 0000318154 (see all company filings)

EIN.: 953540776 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37702 | Film No.: 26654868
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)